摘要
目的探究西妥昔单抗联合三维适形放疗对中晚期食管癌患者血清肿瘤标志物水平、新生血管指标水平及生存情况的影响。方法根据治疗方法的不同将62例中晚期食管癌患者分为对照组和观察组,每组31例。两组患者均予以常规化疗和三维适形放疗,观察组在此基础上予以西妥昔单抗静脉滴注。比较两组患者治疗前后的血清肿瘤标志物水平、新生血管指标水平及生存情况。结果治疗后,两组患者的癌胚抗原(CEA)、糖类抗原125(CA125)、细胞角质蛋白19片段抗原21-1(CYFRA21-1)、鳞状细胞癌抗原(SCCAg)、血管内皮生长因子(VEGF)、血管内皮生长因子受体1(VEGFR1)水平均低于本组治疗前(P﹤0.05),且观察组患者的上述指标水平均明显低于对照组(P﹤0.01)。观察组患者的3年生存率高于对照组,3年内转移率、复发率均低于对照组(P﹤0.05)。结论在常规化疗和三维适形放疗的基础上联合西妥昔单抗治疗中晚期食管癌患者,能够有效降低血清肿瘤标志物水平,抑制肿瘤新生血管形成,改善患者预后,值得临床推广应用。
Objective To investigate the effect of cetuximab combined three-dimensional conformal radiotherapy on levels of serum tumor markers,neovascularization indexes and survival of patients with moderate and advanced esophageal cancer.Method Sixty-two patients with moderate and advanced esophageal cancer were randomly divided into the control group and the observation group,31 cases each.Both groups received conventional chemotherapy and three-dimensional conformal radiotherapy,with additional intravenous cetuximab administration in the observation group.The levels of serum tumor markers,neovascularization indexes and survival were compared.Result After treatment,the levels of carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),cyto-keratin 19 fragment antigen 21-1(CYFRA21-1),squamous cell carcinoma antigen(SCCAg),vascular endothelial growth factor(VEGF)and vascular endothelial growth factor receptor 1(VEGFR1)in the two groups all decreased(P<0.05),and those in the observation group were significantly lower than those in the control group(P<0.01).The 3-year survival rate in the observation group was significantly higher than that in the control group,the metastatic rate and recurrence rate significantly lower than those in the control group(P<0.05).Conclusion Conventional chemotherapy and three-dimensional conformal radiotherapy combined cetuximab and can significantly decrease the levels of serum tumor markers in patients with moderate and advanced esophageal cancer,inhibit the formation of tumor neovascularization,and improve the prognosis of patients,which is worthy of clinical promotion and application.
作者
饶石磊
杨峥
赵得堡
张萌
RAO Shilei;YANG Zheng;ZHAO Debao;ZHANG Meng(Department of Radiotherapy,Nanyang Central Hospital,Nanyang 473000,He’nan,China;Department of Oncology,Nanyang Central Hospital,Nanyang 473000,He’nan,China;Department of Digestive Surgery,Nanyang Central Hospital,Nanyang 473000,He’nan,China)
出处
《癌症进展》
2020年第3期300-302,306,共4页
Oncology Progress
关键词
食管癌
西妥昔单抗
三维适形放疗
肿瘤新生血管
癌胚抗原
鳞状细胞癌抗原
esophageal cancer
cetuximab
three-dimensional conformal radiotherapy
tumor neovascularization
carcinoembryonic antigen
squamous cell carcinoma antigen
